Casey Harrell can now talk for twelve hours at a stretch. Two years ago, he could not talk at all. The ALS he was diagnosed with several years earlier had progressively destroyed the motor neurons controlling the muscles of his face and throat, leaving him with the symptoms doctors call dysarthria and, eventually, anarthria — the inability to speak intelligibly even with substantial effort. Harrell still knew what he wanted to say. The neural commands his brain was sending toward the muscles of his lips, tongue, jaw, and larynx were intact. The muscles themselves no longer responded. What the BrainGate clinical trial team at UC Davis did, in a July 2023 surgery that took several hours, was implant four small arrays of microelectrodes into the left precentral gyrus of Harrell’s brain — the region of the speech motor cortex that ordinarily sends those commands to those muscles. The arrays contain 256 electrodes between them. The electrodes record the firing patterns of individual neurons in real time. Machine-learning software running on a nearby computer translates the patterns into the words that Harrell, despite no longer being able to produce them with his mouth, is still trying to say.
According to UC Davis Health’s June 2026 announcement of the latest results, the system now operates at approximately 99 percent accuracy across a working vocabulary of 125,000 words — essentially every word an English-speaking adult would ordinarily need. Harrell’s average speaking rate via the device is approximately 56 words per minute, comparable to slow natural conversation. He has used the system at home, without researchers present, for more than 3,800 hours over a 400-day continuous-use period — averaging roughly five hours of daily use, with maximum single sessions of approximately twelve hours. He has produced more than 183,000 sentences and approximately two million words. His synthesised voice is modelled on recordings of his own pre-ALS voice. When he first heard it during the early trial phase, his own comment was: “It feels a lot like me.”
What changed between 2024 and 2026
The BrainGate team’s first publication on Harrell’s case, in the New England Journal of Medicine in August 2024, established that the basic approach worked — that brain activity recorded from the speech motor cortex could be decoded into fluent speech with high accuracy, in a setting with researchers present and a constrained working session. The June 2026 paper documents something fundamentally different: the same patient continuing to use the same system, but now in an independent home setting, operated by his own care team rather than by researchers, for thousands of hours over multiple years. As reported by ScienceAlert’s coverage of the latest results, this transition — from a proof-of-concept demonstration in a research lab to a sustained, independent communication tool used as part of daily life — is the genuinely novel achievement that the BrainGate team is reporting.
David Brandman, the UC Davis neurosurgeon who implanted the device and co-led the research, framed the shift directly: “For years, BCIs have been proof-of-concept devices that lived in highly controlled research labs. This work shows that we may have crossed a threshold, by empowering a person with paralysis to speak on his own terms.” The practical difference is substantial. A device that requires researchers to be physically present every time it is used can demonstrate scientific feasibility but cannot become part of a person’s actual life. A device that the patient’s regular home care team can connect every morning and disconnect every evening, with no specialist intervention required, can. Harrell has been doing the latter for two years.
What the system actually does
The fundamental insight underlying the BrainGate speech BCI is that the brain continues to send speech commands even after the muscles can no longer execute them. When Harrell attempts to speak, the neurons in his speech motor cortex fire in patterns that are essentially identical to the patterns they would have produced if he could still move his speech muscles normally. The implanted microelectrodes record those firing patterns from approximately 256 individual neurons. The decoding software, trained on Harrell’s specific neural signatures during initial calibration sessions, identifies which phonemes he is trying to produce and assembles them into words. Per The Next Web’s analysis of the BRAND platform that powers the decoding, the system uses a custom machine-learning architecture optimised for real-time speech reconstruction, with continuous adaptation to changes in the neural signal over time.
One of the more remarkable aspects of the system is its inclusion of a deliberate “privacy mode,” in which Harrell can disable data recording when he does not want his neural activity captured or used to train future versions of the decoder. The feature exists because the technology raises real concerns about the boundary between intended speech and unspoken thought. Brain-computer interfaces, by their nature, record neural activity that the user may not have chosen to externalise. The BrainGate team has been careful to design the system so that the user controls what gets recorded and what does not.
What this means for the broader field
The Harrell case is part of a broader convergence in the BCI field that has been gathering pace over the past several years. As covered by a Clinical Trials Arena analysis of the BCI clinical trial landscape, the BrainGate consortium — which has been running clinical trials of brain-computer interfaces since the early 2000s, and now spans Brown University, Massachusetts General Hospital, the VA, and UC Davis — is one of several parallel efforts working on the same general problem. Elon Musk’s Neuralink, Synchron, Paradromics, and the UCSF and Stanford BCI groups have all produced demonstrations of varying scope and ambition. The BrainGate Harrell case is, at present, the most extensively documented sustained-use BCI result in the published literature, but it sits within a broader trajectory in which the basic technology is moving from research curiosity to clinical reality.
For the approximately 30,000 Americans currently living with ALS, the practical implications of the Harrell case are limited in the short term. The technology remains experimental, requires invasive surgery, and is not yet commercially available outside the clinical trial setting. Scaling the approach to a second patient, a tenth patient, a hundredth patient will require substantial work on hardware durability, surgical standardisation, software adaptation across individual neural signatures, regulatory approval, and the long list of practical and economic questions that any new medical device must answer before becoming generally available. None of these are insurmountable. None of them are immediate. Harrell himself is now able to communicate, work, and participate in family and social life in ways that were not available to him two years ago. The question of how soon the same becomes true for other ALS patients, for stroke survivors with severe communication impairment, for people with locked-in syndrome, and for the broader population of patients with severe paralysis is now a question of engineering, manufacturing, and policy rather than of fundamental scientific possibility. The threshold the BrainGate team is now claiming to have crossed, in Brandman’s framing, is the one between proof-of-concept and tool. Whether the rest of the field follows, and how quickly, will define the next decade of BCI research.
